



Acarix Partners with Geo-Med to Extend the Availability of the CADScor System for Veterans

OKLAHOMA CITY — Acarix, a pioneer in the development of groundbreaking acoustic-based cardiac diagnostic solutions, is proud to announce a new strategic partnership with Geo-Med, LLC, a renowned Service-Disabled Veteran-Owned Small Business that specializes in medical and surgical products for the Department of Veterans Affairs and Department of Defense.

This partnership signifies Acarix's dedication towards enhancing the availability of advanced medical technologies to America's veterans. Geo-Med's deep expertise in providing high-quality medical products to the VA and Department of Defense, along with their insight into VA procurement, will be instrumental in ensuring that the CADScor System by Acarix reaches the veterans who need it most.

Aamir Mahmood, President and CEO of Acarix, remarked, "This is a monumental win for Acarix as we unite with Geo-Med's considerable capabilities and reach. Together, we are set to drive forward the presence of innovative and life-saving cardiac diagnostic tools such as the CADScor® System, enhancing the quality of care available to these brave veterans."

Mike Locke, CEO of Geo-Med, added, "Our mission has always focused on delivering the best medical solutions to our servicemen and women. Partnering with Acarix aligns perfectly with our goal, leveraging their pioneering CADScor System to add exceptional value to our product offerings and ultimately to the healthcare of our veterans."

The CADScor System by Acarix, known for its efficiency and accurate low-risk stratification in assessing coronary artery disease (CAD) at the point of care, will now be more readily accessible within federal medical facilities, ensuring critical advancements in medical technology are within reach for the men and women who have served the United States.

For further details about Geo-Med, please visit www.geomedsdvo.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

05 February 2025 09:35:00 CET



For more information, contact

Ashley Wilson, phone +1405 413 5201, email awilson@saxum.com

Attachments

[Acarix Partners with Geo-Med to Extend the Availability of the CADScor System for Veterans](#)